Gentian Diagnostics AS (GENT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gentian Diagnostics AS (GENT) has a cash flow conversion efficiency ratio of 0.208x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr42.59 Million ≈ $4.48 Million USD) by net assets (Nkr204.96 Million ≈ $21.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gentian Diagnostics AS - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Gentian Diagnostics AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Gentian Diagnostics AS carry for a breakdown of total debt and financial obligations.
Gentian Diagnostics AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gentian Diagnostics AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DK-Lok Corporation
KQ:105740
|
0.012x |
|
Widodo Makmur Perkasa PT
JK:WMPP
|
-0.003x |
|
Siebert Financial Corp
NASDAQ:SIEB
|
0.005x |
|
Metrofile
JSE:MFL
|
0.237x |
|
Ozsu Balik Uretim A.S.
IS:OZSUB
|
0.430x |
|
Pc Iletisim ve Medya Hizmetleri Sanayi Ticaret AS
IS:PCILT
|
0.099x |
|
Woosu AMS Co.Ltd
KQ:066590
|
0.066x |
|
GO Element Co. Ltd.
KQ:311320
|
0.044x |
Annual Cash Flow Conversion Efficiency for Gentian Diagnostics AS (2013–2025)
The table below shows the annual cash flow conversion efficiency of Gentian Diagnostics AS from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Gentian Diagnostics AS market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr204.96 Million ≈ $21.57 Million |
Nkr42.59 Million ≈ $4.48 Million |
0.208x | +199.65% |
| 2024-12-31 | Nkr194.05 Million ≈ $20.42 Million |
Nkr13.46 Million ≈ $1.42 Million |
0.069x | -34.22% |
| 2023-12-31 | Nkr146.64 Million ≈ $15.43 Million |
Nkr15.46 Million ≈ $1.63 Million |
0.105x | +216.49% |
| 2022-12-31 | Nkr154.17 Million ≈ $16.22 Million |
Nkr-13.95 Million ≈ $-1.47 Million |
-0.090x | +41.54% |
| 2021-12-31 | Nkr174.77 Million ≈ $18.39 Million |
Nkr-27.05 Million ≈ $-2.85 Million |
-0.155x | -293.16% |
| 2020-12-31 | Nkr194.58 Million ≈ $20.48 Million |
Nkr-7.66 Million ≈ $-806.16K |
-0.039x | +61.84% |
| 2019-12-31 | Nkr208.24 Million ≈ $21.91 Million |
Nkr-21.48 Million ≈ $-2.26 Million |
-0.103x | -132.78% |
| 2018-12-31 | Nkr245.87 Million ≈ $25.87 Million |
Nkr-10.90 Million ≈ $-1.15 Million |
-0.044x | +53.27% |
| 2017-12-31 | Nkr196.48 Million ≈ $20.67 Million |
Nkr-18.63 Million ≈ $-1.96 Million |
-0.095x | -38.67% |
| 2016-12-31 | Nkr115.54 Million ≈ $12.16 Million |
Nkr-7.90 Million ≈ $-831.48K |
-0.068x | -40.53% |
| 2015-12-31 | Nkr95.06 Million ≈ $10.00 Million |
Nkr-4.63 Million ≈ $-486.79K |
-0.049x | +81.55% |
| 2014-12-31 | Nkr7.39 Million ≈ $778.15K |
Nkr-1.95 Million ≈ $-205.27K |
-0.264x | -117.56% |
| 2013-12-31 | Nkr1.62 Million ≈ $170.46K |
Nkr2.43 Million ≈ $256.10K |
1.502x | -- |
About Gentian Diagnostics AS
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more